Globally, more people shall be exposed to the risk of visual impairment as a result of population growth and aging. Among the 2.2 billion people suffering from vision impairment or blindness at least 1 billion have vision impairment that could have been prevented or is yet to be addressed. Main causes of visual impairment include: uncorrected refractive errors, cataracts, age-related macular degeneration, glaucoma, and diabetic retinopathy, etc.
Among them, age-related macular degeneration, glaucoma, and cataracts are the top three causes of blindness in the world, and are prevalent among elderly patients aged 50 and older.
In order to treat age-related macular degeneration, one of top three causes of blindness, we have conducted studies for more than a decade. Our research has shown that ocular diseases such as wet age-related macular degeneration (nAMD) , diabetic macular edema (DME), pathologic myopia choroidal neovascularization（pmCNV）and retinal vein occlusion (RVO) can be effectively treated by blocking the signal transmission mediated by the vascular endothelial growth factor (VEGF), inhibiting pathological neovascularization, and improving vascular penetration. As a result, a new-generation anti-VEGF fusion protein molecule, Conbercept, has been developed and brought to the world stage.
Conbercept is a 100% humanized drug targeting VEGFA, B, PLGF, etc. Due to its superior molecular structure, Conbercept is safer and more efficient, and has greater binding affinity and a longer duration of action.
Up until now, Conbercept has provided more than 2 million-time injections in China with better and more effective treatment.In addition, through asset merger and acquisition, we have obtained a new-generation treatment against glaucoma, i.e. CO2 laser-assisted deep sclerectomy, hence bringing glaucoma patients a safer, long-acting, and convenient treatment regimen.
In modern society, with an increasing use of eyes in study, work, and recreation, various eye diseases have been characterized by increasing prevalence, and particularly trends of high incidence and younger patient ages.
Kanghong Pharmaceutical has been keeping an eye on the development of diseases, and aims to deliver safer and more effective innovations and treatment regimens to more patients. To help patients who require long-term medication, we shall continue to innovate and achieve breakthroughs in reducing the frequency of drug administration and reducing the risks of treatment, so as to bring better treatment experiences and results as well as improved quality of life to more patients.
At the same time, we also hope to put our professional academic advantages to good use by increasing public awareness on eye care, developing good eye care habits, improving regional eye disease screening as well as the development of diagnostic and therapeutic technologies.